NIH to get $2B funding boost in spending bill

The National Institutes of Health (NIH) would receive an additional $2 billion in funding under a Senate appropriations bill, according to The Hill.

With the added funding, the agency’s total budget would grow to about $34 billion, $3 billion above what President Barack Obama had requested. NIH had also received an extra $2 billion from a medical research funding bill passed in December.

The areas that would benefit from the additional funding include:

  • Alzheimer’s research funding would increase by $400 million to $1.39 billion.
  • Precision Medicine Initiative funding would increase by $100 million to $300 million.
  • Anti-opioid programs would get an additional $126 million.
  • Antibiotic resistance research would receive an additional $53 million.

The spending bill, which covers both HHS and the U.S. Department of Labor, would reportedly also provide a boost to the National Cancer Institute, which is welcome news to the American Association for Cancer Research (AACR).

“During the past year, we have seen a ground swell of bipartisan support for NIH on Capitol Hill, and today’s mark-up shows that leaders in Congress understand the value and importance of ensuring that NIH’s annual budget increases are robust, sustained, and predictable,” AACR CEO Margaret Foti, MD, PhD, said in a statement.

While reaction to the additional funding is positive, some groups have expressed concerns to The Hill about whether NIH will benefit at the expense of other health agencies, like the Centers for Disease Control and Prevention (CDC).

“It’s an amazing number, but the devil’s in the details,” said Ellie Dehoney, the vice president for policy and advocacy for Research!America. “So far, so amazing.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.